Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2010 Jul;54(7):2847-54. doi: 10.1128/AAC.01567-09. Epub 2010 May 3.

2.

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Gumbo T, Dona CS, Meek C, Leff R.

Antimicrob Agents Chemother. 2009 Aug;53(8):3197-204. doi: 10.1128/AAC.01681-08. Epub 2009 May 18.

3.

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.

Srivastava S, Pasipanodya JG, Ramachandran G, Deshpande D, Shuford S, Crosswell HE, Cirrincione KN, Sherman CM, Swaminathan S, Gumbo T.

EBioMedicine. 2016 Apr;6:126-38. doi: 10.1016/j.ebiom.2016.02.040. Epub 2016 Feb 27.

4.

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

Sharma SK, Sharma A, Kadhiravan T, Tharyan P.

Cochrane Database Syst Rev. 2013 Jul 5;(7):CD007545. doi: 10.1002/14651858.CD007545.pub2. Review.

PMID:
23828580
5.

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

Sharma SK, Sharma A, Kadhiravan T, Tharyan P.

Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962.

PMID:
25404581
6.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators..

Ann Intern Med. 2002 Oct 15;137(8):640-7.

PMID:
12379063
7.

Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.

Sahota T, Della Pasqua O.

Antimicrob Agents Chemother. 2012 Nov;56(11):5442-9. doi: 10.1128/AAC.05988-11. Epub 2012 Jul 9.

8.
9.

[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].

Camacho A, Pérez-Camacho I, Rivero A, Natera C, García-Lázaro M, Castón JJ, Gallo M, Kindelán JM, Torre-Cisneros J.

Enferm Infecc Microbiol Clin. 2010 Apr;28(4):239-44. doi: 10.1016/j.eimc.2009.04.003. Epub 2009 Aug 3. Spanish.

PMID:
19647900
10.

Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis.

Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE, Peloquin CA.

Pharmacotherapy. 2002 Jun;22(6):686-95.

PMID:
12066959
11.
12.

Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.

Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, Sreenivas V, Singh S.

Clin Infect Dis. 2010 Mar 15;50(6):833-9. doi: 10.1086/650576.

PMID:
20156055
13.

Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.

Gupta P, Roy V, Sethi GR, Mishra TK.

Br J Clin Pharmacol. 2008 Mar;65(3):423-7. Epub 2007 Dec 17.

14.

Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program.

Roy V, Sahni P, Gupta P, Sethi GR, Khanna A.

Indian Pediatr. 2012 Sep;49(9):721-5. Epub 2011 Jan 17.

15.

Biowaiver monographs for immediate release solid oral dosage forms: pyrazinamide.

Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM.

J Pharm Sci. 2008 Sep;97(9):3709-20. doi: 10.1002/jps.21250.

17.

Hepatotoxicity of pyrazinamide: cohort and case-control analyses.

Chang KC, Leung CC, Yew WW, Lau TY, Tam CM.

Am J Respir Crit Care Med. 2008 Jun 15;177(12):1391-6. doi: 10.1164/rccm.200802-355OC. Epub 2008 Apr 3.

PMID:
18388355
18.

Six-month therapy for abdominal tuberculosis.

Jullien S, Jain S, Ryan H, Ahuja V.

Cochrane Database Syst Rev. 2016 Nov 1;11:CD012163. Review.

PMID:
27801499
19.

Antituberculosis drugs and hepatotoxicity.

Yew WW, Leung CC.

Respirology. 2006 Nov;11(6):699-707. Review.

PMID:
17052297

Supplemental Content

Support Center